KDR and neoplasm: As a multitarget antiangiogenic TKI, anlotinib could firstly inhibit the VEGFR to normalize the tumor vessels, reducing tissue hypoxia and enhancing the delivery of other antitumor agents such as immune checkpoint inhibitor (32).